WHO ICTRP trial
TACE sequential MWA combined with carririzumab and apatinib in the treatment of…
ChiCTR2100048076 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2100048076 |
|---|---|
| Public title | TACE sequential MWA combined with carririzumab and apatinib in the treatment of hepatocellular carcinoma: a prospective, open, single-arm, single-center clinical study |
| Scientific title | TACE sequential MWA combined with carririzumab and apatinib in the treatment of hepatocellular carcinoma: a prospective, open, single-arm, single-center clinical study |
| Primary sponsor | The First Affiliated Hospital of Bengbu Medical College |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Countries | China |
| Conditions | Hepatocellular carcinoma(HCC) |
| Interventions | Case series:Camrelizumab + apatinib+TACE sequential MWA |
| Registration date | Jun 30, 2021 |
| Target size | Case series:40 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: